Effect of acupuncture with donepezil based on syndrome differentiation on cognitive function in patients with mild-to-moderate Alzheimer's disease: a study protocol for a multicenter randomized controlled trial

Qin-Hui Fu, Jian Pei, Hou-Guang Zhou, Tao Wang, Yi-Jun Zhan, Lin Tao, Jia Xu, Qian Zhou, Liao-Yao Wang, Qin-Hui Fu, Jian Pei, Hou-Guang Zhou, Tao Wang, Yi-Jun Zhan, Lin Tao, Jia Xu, Qian Zhou, Liao-Yao Wang

Abstract

Background: There has been a rapid increase in the worldwide prevalence of Alzheimer's disease (AD). Previous studies have shown that acupuncture can improve neurological and cognitive function; however, the utility of applying acupuncture in patients with AD remains unclear. This study protocol describes a clinical trial for evaluating the efficacy and safety of acupuncture based on syndrome differentiation with donepezil hydrochloride on cognitive function in patients with AD.

Methods/design: This multicenter randomized controlled trial commenced on February 1, 2019, at the Shanghai Longhua Hospital of TCM, Shanghai Huashan Hospital of Fudan University, and Shanghai Mental Health Center, and will conclude on June 30, 2022. The study will recruit 184 patients randomly divided into an acupuncture group or a control group at a 1:1 ratio. All participants will receive donepezil hydrochloride (5 mg/day), and those in the acupuncture group will receive acupuncture based on syndrome differentiation with donepezil for 12 weeks. The primary outcome will be the post-treatment change in the Alzheimer's Disease Assessment Scale-cognition score at 12 weeks. The secondary outcomes will be the efficacy scores of the Minimum Mental State Examination, Alzheimer's Disease Cooperative Research Activity-Daily Life, and Quality of Life-Alzheimer's Disease. All assessments will be performed at baseline, after treatment (week 12), and at follow-up (weeks 24 and 36).

Discussion: This trial may provide high-quality evidence for the efficacy of acupuncture in the treatment of AD. The results of this study will be published in peer-reviewed journals.

Trial registration: ClinicalTrials.gov NCT03810794 . Registered on 17 January 2019.

Keywords: Acupuncture; Alzheimer’s disease; Randomized controlled trial; Study protocol; Syndrome differentiation.

Conflict of interest statement

The authors declare that they have no competing interests.

© 2022. The Author(s).

Figures

Fig. 1
Fig. 1
Flowchart of the trial: the participants will be randomly assigned to the acupuncture group (AG) or control group (CG) at a ratio of 1:1; all the patients will be treated for 12 weeks and be assessed at week 12, week 24, and week 36

References

    1. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789–1858. doi: 10.1016/S0140-6736(18)32279-7.
    1. Jia J, Wang F, Wei C, Zhou A, Jia X, Li F, et al. The prevalence of dementia in urban and rural areas of China. Alzheimers Dement. 2014;10:1–9. doi: 10.1016/j.jalz.2013.01.012.
    1. GBD 2017 DALYs and HALE Collaborators Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392:1859–1922. doi: 10.1016/S0140-6736(18)32335-3.
    1. Jia J, Wei C, Chen S, Li F, Tang Y, Qin W, et al. The cost of Alzheimer's disease in China and re-estimation of costs worldwide. Alzheimers Dement. 2018;14:483–491. doi: 10.1016/j.jalz.2017.12.006.
    1. Fang EF, Scheibye-Knudsen M, Jahn HJ, Li J, Ling L, Guo H, et al. A research agenda for aging in China in the 21st century. Ageing Res Rev. 2015;24(Pt B):197–205. doi: 10.1016/j.arr.2015.08.003.
    1. Yuan J, Zhang Z, Wen H, Hong X, Hong Z, Qu Q, et al. Incidence of dementia and subtypes: A cohort study in four regions in China. Alzheimers Dement. 2016;12(3):262–271. doi: 10.1016/j.jalz.2015.02.011.
    1. Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol. 2014;13(6):614–629. doi: 10.1016/S1474-4422(14)70090-0.
    1. Hampel H, Toschi N, Babiloni C, Baldacci F, Black KL, Bokde ALW, et al. Revolution of Alzheimer Precision Neurology. Passageway of Systems Biology and Neurophysiology. J Alzheimers Dis. 2018;64(s1):S47–S105. doi: 10.3233/JAD-179932.
    1. Ossenkoppele R, Schonhaut DR, Schöll M, Lockhart SN, Ayakta N, Baker SL, et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease. Brain. 2016;139(Pt 5):1551–1567. doi: 10.1093/brain/aww027.
    1. Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt HP, van den Bussche H. Cholinesterase inhibitors for patients with Alzheimer’s disease: systematic review of randomised clinical trials. BMJ. 2005;331:321–327. doi: 10.1136/bmj.331.7512.321.
    1. Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfield S, Ding C. A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology. 2000;54:2269–2276. doi: 10.1212/wnl.54.12.2269.
    1. Molinuevo JL, Berthier ML, Rami L. Donepezil provides greater benefits in mild compared to moderate Alzheimer's disease: implications for early diagnosis and treatment. Arch Gerontol Geriatr. 2011;52:18–22. doi: 10.1016/j.archger.2009.11.004.
    1. Rockwood K. Attainment of treatment goals by people with Alzheimer’s disease receiving galantamine: a randomized controlled trial. CMAJ. 2006;174:1099–1105. doi: 10.1503/cmaj.051432.
    1. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004;291:317–324. doi: 10.1001/jama.291.3.317.
    1. Birks JS, Harvey RJ. Donepezil for dementia due to Alzheimer’s disease. Cochrane Database Syst Rev. 2018;6:CD001190. doi: 10.1002/14651858.CD001190.pub3.
    1. Hansen R, Gartlehner G, Webb PA. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer’s disease: a systematic review and meta-analysis. Clin Interv Aging. 2008;3(2):211–225.
    1. Tampi RR, Dyck CH. Memantine: efficacy and safety in mild-to-severe Alzheimer’s disease. Neuropsychiatr Dis Treat. 2007;3:245–258. doi: 10.2147/nedt.2007.3.2.245.
    1. Wang L, Pei J, Zhan Y, Cai Y. Overview of Meta-Analyses of Five Non-pharmacological Interventions for Alzheimer’s Disease. Front Aging Neurosci. 2020;12:594432. doi: 10.3389/fnagi.2020.594432.
    1. Brown BM, Peiffer JJ, Martins RN. Multiple effects of physical activity on molecular and cognitive signs of brain aging: can exercise slow neurodegeneration and delay Alzheimer’s disease? Mol Psychiatry. 2013;18:864–874. doi: 10.1038/mp.2012.162.
    1. Zhou J, Peng WN, Xu M, Li W, Liu ZS. The effectiveness and safety of acupuncture for patients with Alzheimer disease: a systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore) 2015;94:e933. doi: 10.1097/MD.0000000000000933.
    1. Cao Y, Zhang LW, Wang J, Du SQ, Xiao LY, Tu JF, et al. Mechanisms of acupuncture effect on Alzheimer’s disease in animal- based researches. Curr Top Med Chem. 2016;16:574–578. doi: 10.2174/1568026615666150813144942.
    1. Tan TT, Wang D, Huang JK, Zhou XM, Yuan X, Liang JP, et al. Modulatory effects of acupuncture on brain networks in mild cognitive impairment patients. Neural Regen Res. 2017;12:250–258. doi: 10.4103/1673-5374.200808.
    1. Zeng H, Liu M, Wang P, Kang J, Lu F, Pan L. The effects of acupressure training on sleep quality and cognitive function of older adults: a 1-year randomized controlled trial. Res Nurs Health. 2016;39:328–336. doi: 10.1002/nur.21738.
    1. Tao J, Liu J, Liu W, Huang J, Xue X, Chen X, et al. Tai Chi Chuan and Baduanjin increase grey matter volume in older adults: a brain imaging study. J Alzheimers Dis. 2017;60:389–400. doi: 10.3233/JAD-170477.
    1. Li L, Zhang H, Meng SQ, Qian HZ. An updated meta-analysis of the efficacy and safety of acupuncture treatment for cerebral infarction. PLoS One. 2014;9:e114057. doi: 10.1371/journal.pone.0114057.
    1. Xiao LY, Wang XR, Yang Y, Yang JW, Cao Y, Ma SM, et al. Applications of Acupuncture Therapy in Modulating Plasticity of Central Nervous System. Neuromodulation. 2018;21:762–776. doi: 10.1111/ner.12724.
    1. Feng Q, Bin LL, ZhaiYB XM, Liu ZS, Peng WN. Long-term efficacy and safety of electroacupuncture on improving MMSE in patients with Alzheimer’s disease. Zhongguo Zhen Jiu. 2019;39(3-8). 10.13703/j.0255-2930.2019.01.001 (in Chinese).
    1. Wang Y, Qin WG, Yu CD. Clinical observation on effect of cranial suture acupuncture combined with donepezil hydrochloride tablets for Alzheimer’s disease. World J Acupunct Moxibustion. 2014;24(2):19–24. doi: 10.1016/S1003-5257(14)60020-9.
    1. Teja Y, Helianthi DR, Nareswari I. The Role of Medical Acupuncture Therapy in Alzheimer’s Disease. Med Acupunct. 2021;33(6):396–402. doi: 10.1089/acu.2021.0014.
    1. Tang Y, Shao S, Guo Y, Zhou Y, Cao J, Xu A, et al. Electroacupuncture mitigates hippocampal cognitive impairments by reducing BACE1 deposition and activating PKA in APP/PS1 double transgenic mice. Neural Plast. 2019;2019:2823679. doi: 10.1155/2019/2823679.
    1. Li X, Guo F, Zhang Q, Huo T, Liu L, Wei H, et al. Electro-acupuncture decreases cognitive impairment and promotes neurogenesis in the APP/PS1 transgenic mice. BMC Complement Altern Med. 2014;14:37. doi: 10.1186/1472-6882-14-37.
    1. Cheng H, Yu J, Jiang Z, Zhang X, Liu C, Peng Y, et al. Acupuncture improves cognitive deficits and regulates the brain cell proliferation of SAMP8 mice. Neurosci Lett. 2008;432:111–116. doi: 10.1016/j.neulet.2007.12.009.
    1. Dong W, Guo W, Zheng X, Wang F, Chen Y, Zhang W, et al. Electro-acupuncture improves cognitive deficits associated with AMPK activation in SAMP8 mice. Metab Brain Dis. 2015;30:777–784. doi: 10.1007/s11011-014-9641-1.
    1. Guo HD, Tian JX, Zhu J, Li L, Sun K, Shao SJ, et al. Electroacupuncture Suppressed Neuronal Apoptosis and Improved Cognitive Impairment in the AD Model Rats Possibly via Downregulation of Notch Signaling Pathway. Evid Based Complement Alternat Med. 2015;2015:393569. doi: 10.1155/2015/393569.
    1. Lu Y, Huang Y, TangC SB, Cui S, Yang J, et al. Brain areas involved in the acupuncture treatment of AD model rats: a PET study. BMC Complement Altern Med. 2014;14:178. doi: 10.1186/1472-6882-14-178.
    1. Cui SY, Xu MZ, Huang JT, Wang QM, Lai X, Nie B, et al. Cerebral Responses to Acupuncture at GV24 and Bilateral GB13 in Rat Models of Alzheimer's Disease. Behav Neurol. 2018;2018:8740284. doi: 10.1155/2018/8740284.
    1. Zhou Q, Fu QH, Pei J. Research progress on diagnostic criteria of TCM syndromes in Alzheimer's disease. Shanghai J Tradit Chin Med. 2020;54(12):91–96. doi: 10.16305/j.1007-1334.2020.2003339.
    1. Wang J, Lin SM. Considerations on simultaneous treatment of heart-kidney in Alzheimer’s disease. Shanghai J Tradit Chin Med. 2011;45:22–23. doi: 10.16305/j.1007-1334.2011.09.010.
    1. Chan A-W, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin J, et al. SPIRIT 2013 Explanation and Elaboration: Guidance for protocols of clinical trials. BMJ. 2013;346:e7586. doi: 10.1136/bmj.e7586.
    1. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007;6:734–746. doi: 10.1016/S1474-4422(07)70178-3.
    1. Yu L, Lin SM, Zhou RQ, Tang WJ, Huang PX, Dong Y, et al. Chinese herbal medicine for patients with mild to moderate Alzheimer disease based on syndrome differentiation: a randomized controlled trial. J Chin Integr Med. 2012;10(7):766–776. doi: 10.3736/jcim20120707.
    1. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984;141:1356–1364. doi: 10.1176/ajp.141.11.1356.
    1. Wang H, Yu X, Li S, Chen Y, Li H, He J. The cognitive subscale of Alzheimer’s Disease Assessment Scale, Chinese version in staging of Alzheimer disease. Alzheimer DisAssocDisord. 2004;18:231–235.
    1. Mohs RC, Cohen L. Alzheimer’s Disease Assessment Scale (ADAS) Psychopharmacol Bull. 1988;24:627–628.
    1. Galasko D, Bennett D, Sano M, Ernesto C, Thomas R, Grundman M, et al. An inventory to assess activities of daily living for clinical trials in Alzheimer’s Disease. Alzheimer Dis Assoc Disord. 1997;11:S33–S39. doi: 10.1097/00002093-199700112-00005.
    1. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189–198. doi: 10.1016/0022-3956(75)90026-6.
    1. Logsdon RG, Gibbons LE, McCurry SM, Teri L. Quality of life in Alzheimer’s disease: patient and caregiver reports. J Mental Health Aging. 1999;5:21–32.
    1. Logsdon RG, Gibbons LE, McCurry SM, Teri L. Assessing quality of life in older adults with cognitive impairment. Psychosom Med. 2002;64:510–519. doi: 10.1097/00006842-200205000-00016.
    1. Wang YS, Xu J, Fu QH, Pei J. Acupuncture combined with medicine for cognitive functions and life quality of patients with Alzheimer’ s disease: a systematic review. Shanghai J Tradit Chin Med. 2019;53(01):19–25. doi: 10.16305/j.1007-1334.2019.01.005.
    1. Jia Y, Zhang X, Yu J, Han J, Yu T, Shi J, et al. Acupuncture for patients with mild to moderate Alzheimer's disease: a randomized controlled trial. BMC Complement Altern Med. 2017;17:556. doi: 10.1186/s12906-017-2064-x.
    1. Tian JZ, Shi J, Ni JN, Wei MQ, Zhang XK, Chen KJ, et al. Sequential Therapy Based on Evolvement of Patterns: A New Model for Treatment of Alzheimer's Disease. Chin J Integr Med. 2019;25(8):565–573. doi: 10.1007/s11655-019-3066-y.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner